Head-To-Head Contrast: Ligand Pharmaceuticals (NASDAQ:LGND) & WAVE Life Sciences (NASDAQ:WVE)

WAVE Life Sciences (NASDAQ:WVE – Get Free Report) and Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Risk and Volatility

WAVE Life Sciences has a beta of -1.4, meaning that its stock price is 240% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.

Profitability

This table compares WAVE Life Sciences and Ligand Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
WAVE Life Sciences -296.86% -44.66% -36.80%
Ligand Pharmaceuticals 20.27% 5.22% 2.74%

Valuation and Earnings

This table compares WAVE Life Sciences and Ligand Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
WAVE Life Sciences $70.92 million 7.98 -$204.38 million ($1.07) -2.68
Ligand Pharmaceuticals $268.09 million 22.51 $124.45 million $2.24 134.69

Ligand Pharmaceuticals has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for WAVE Life Sciences and Ligand Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WAVE Life Sciences 1 2 15 2 2.90
Ligand Pharmaceuticals 0 1 8 0 2.89

WAVE Life Sciences presently has a consensus target price of $20.44, suggesting a potential upside of 612.35%. Ligand Pharmaceuticals has a consensus target price of $355.38, suggesting a potential upside of 17.79%. Given WAVE Life Sciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe WAVE Life Sciences is more favorable than Ligand Pharmaceuticals.

Summary

Ligand Pharmaceuticals beats WAVE Life Sciences on 10 of the 15 factors compared between the two stocks.

About WAVE Life Sciences

(Get Free Report)

WAVE Life Sciences Ltd. is a biotechnology company developing RNA-based medicines for genetically defined diseases. Founded in 2012, the company is headquartered in Cambridge, Massachusetts, and uses its oligonucleotide chemistry and drug-design capabilities to develop treatments intended to alter or regulate gene expression. Its research includes antisense oligonucleotide therapies and RNA-editing approaches. Programs have targeted conditions such as Huntington’s disease and alpha-1 antitrypsin deficiency, with the latter exploring RNA editing to address a disease-causing genetic variant.

About Ligand Pharmaceuticals

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.